{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:32:08Z","timestamp":1791037928745,"version":"4.1.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","license":[{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,26]]},"abstract":"<jats:p>No study has evaluated the effect of therapeutic granulocyte colony-stimulating factor (G-CSF) in preventing recurrence of febrile neutropenia (FN) and survival outcomes in gynecologic cancer patients. Objective of this study is to optimize and to identify the use of G-CSF and identify the critical factors for preventing the recurrence of FN in women undergoing chemotherapy for the treatment of gynecologic cancer.<\/jats:p>\n                  <jats:p>\n                    The medical records of consecutive patients who underwent chemotherapy for the treatment of gynecologic cancer and experienced FN at least once were retrospectively reviewed. Clinico-laboratory variables were compared between those with and without recurrence of FN to identify risk factors for the recurrence and the most optimal usage of G-CSF that can prevent FN. Student\n                    <jats:italic toggle=\"yes\">t<\/jats:italic>\n                    test,\n                    <jats:italic toggle=\"yes\">\u03c7<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    test, and multivariate Cox regression analysis were used.\n                  <\/jats:p>\n                  <jats:p>\n                    A total of 157 patients who met the inclusion criteria were included. Of 157, 49 (31.2%) experienced recurrence of FN. Age \u226555 years (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = .043), previous lines of chemotherapy \u22641 (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = .002), thrombocytopenia (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = .025), total dose (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = .003), and maximum daily dose (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = .009) of G-CSF were significantly associated with recurrence of FN. Multiple regression analysis showed that age \u226555 years (HR, 2.42; 95% CI, 1.14\u20135.14;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = .022), previous chemotherapy \u22641 (HR, 4.01; 95% CI, 1.40\u201311.55;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = .010), and maximum daily dose of G-CSF \u2264600 \u03bcg (HR, 5.18; 95% CI, 1.12\u201324.02;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = .036) were independent risk factors for recurrent FN. Multivariate Cox regression analysis showed that a maximum daily dose of G-CSF \u2264600 \u03bcg was the only independent risk factor for short recurrence-free survival of FN (HR, 4.75; 95% CI, 1.15\u201319.56;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = .031).\n                  <\/jats:p>\n                  <jats:p>Dose-dense administration of G-CSF &gt;600 \u03bcg\/day could prevent recurrence of FN in women who undergo chemotherapy for the treatment of gynecologic cancer and FN. Old age and FN at early lines of chemotherapy seem to be associated with FN recurrence.<\/jats:p>","DOI":"10.1097\/md.0000000000030155","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T10:01:49Z","timestamp":1661853709000},"page":"e30155","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Maximum daily dose of G-CSF is critical for preventing recurrence of febrile neutropenia in patients with gynecologic cancer: A case\u2013control study"],"prefix":"10.1097","volume":"101","author":[{"given":"Nam Kyeong","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea"},{"name":"Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1196-369X","authenticated-orcid":false,"given":"Dong Hoon","family":"Suh","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea"},{"name":"Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kidong","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea"},{"name":"Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hong","family":"No","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea"},{"name":"Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Beom","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea"},{"name":"Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20250707","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1097\/CAD.0000000000000279","article-title":"Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy.","volume":"26","author":"Hashiguchi","year":"2015","journal-title":"Anticancer Drugs"},{"key":"R3-20250707","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2017.77.6211","article-title":"Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update.","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"key":"R4-20250707","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.3802\/jgo.2020.31.e62","article-title":"Incidence and clinical course of septic shock in neutropenic patients during chemotherapy for gynecological cancers.","volume":"31","author":"Yoo","year":"2020","journal-title":"J Gynecol Oncol"},{"key":"R5-20250707","first-page":"19","article-title":"Impact of neutropenia on delivering planned chemotherapy for solid tumours.","volume":"17","author":"Khan","year":"2008","journal-title":"Eur J Cancer Care (Engl)"},{"key":"R6-20250707","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4049\/jimmunol.1500861","article-title":"G-CSF and GM-CSF in neutropenia.","volume":"195","author":"Mehta","year":"2015","journal-title":"J Immunol"},{"key":"R7-20250707","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.","volume":"25","author":"Kuderer","year":"2007","journal-title":"J Clin Oncol"},{"key":"R8-20250707","first-page":"Cd007913","article-title":"Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.","volume":"10","author":"Renner","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"R9-20250707","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0002-9343(96)90006-6","article-title":"Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia.","volume":"100","author":"Anaissie","year":"1996","journal-title":"Am J Med"},{"key":"R10-20250707","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1200\/JCO.1998.16.9.2930","article-title":"Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.","volume":"16","author":"Ravaud","year":"1998","journal-title":"J Clin Oncol"},{"key":"R11-20250707","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00006454-199403000-00006","article-title":"Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children.","volume":"13","author":"Riikonen","year":"1994","journal-title":"Pediatr Infect Dis J"},{"key":"R12-20250707","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.1996.14.2.619","article-title":"Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia.","volume":"14","author":"Vellenga","year":"1996","journal-title":"J Clin Oncol"},{"key":"R13-20250707","first-page":"Cd003039","article-title":"Colony-stimulating factors for chemotherapy-induced febrile neutropenia.","volume":"2014","author":"Mhaskar","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R14-20250707","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00520-017-3854-x","article-title":"A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.","volume":"26","author":"Dale","year":"2018","journal-title":"Support Care Cancer"},{"key":"R15-20250707","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1200\/JCO.2005.05.645","article-title":"Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials.","volume":"23","author":"Clark","year":"2005","journal-title":"J Clin Oncol"},{"key":"R16-20250707","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","article-title":"Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review.","volume":"90","author":"Lyman","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"R17-20250707","doi-asserted-by":"crossref","first-page":"7582730","DOI":"10.1155\/2018\/7582730","article-title":"Chemotherapeutic drugs and mitochondrial dysfunction: focus on doxorubicin, trastuzumab, and sunitinib.","volume":"2018","author":"Gorini","year":"2018","journal-title":"Oxid Med Cell Longev"},{"key":"R18-20250707","doi-asserted-by":"crossref","first-page":"6841581","DOI":"10.1155\/2020\/6841581","article-title":"Utilizing melatonin to alleviate side effects of chemotherapy: a potentially good partner for treating cancer with ageing.","volume":"2020","author":"Ma","year":"2020","journal-title":"Oxid Med Cell Longev"},{"key":"R19-20250707","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1002\/cncr.25691","article-title":"Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy.","volume":"117","author":"Lyman","year":"2011","journal-title":"Cancer"},{"key":"R20-20250707","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1365-2141.2008.07514.x","article-title":"Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study.","volume":"144","author":"Pettengell","year":"2009","journal-title":"Br J Haematol"},{"key":"R21-20250707","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF01696346","article-title":"Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF.","volume":"67","author":"Laughlin","year":"1993","journal-title":"Ann Hematol"},{"key":"R22-20250707","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ajh.22242","article-title":"Congenital and acquired neutropenias consensus guidelines on therapy and follow-up in childhood from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato-Oncologia Pediatrica).","volume":"87","author":"Fioredda","year":"2012","journal-title":"Am J Hematol"},{"key":"R23-20250707","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/sj.bmt.1705722","article-title":"Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the research on adverse drug events and reports project.","volume":"40","author":"Tigue","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"R24-20250707","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.transci.2013.07.036","article-title":"A rare but severe complication of filgrastim in a healthy donor: splenic rupture.","volume":"50","author":"Akyol","year":"2014","journal-title":"Transfus Apher Sci"},{"key":"R25-20250707","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/jnci\/djk028","article-title":"Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.","volume":"99","author":"Hershman","year":"2007","journal-title":"J Natl Cancer Inst"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000030155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:11:47Z","timestamp":1786036307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000030155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":24,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000030155","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,26]]}}}